Defatted powder of Arachis hypogaea L., semen (peanuts) (Palforzia®). HTA ID: 22019

Assessment Status NCPE Assessment Process Complete
HTA ID 22019
Drug Defatted powder of Arachis hypogaea L., semen (peanuts)
Brand Palforzia®
Indication For the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet.
Assessment Process
Rapid review commissioned 01/04/2022
Rapid review completed 04/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Palforzia® compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/05/2022
Pre-submission consultation with Applicant 22/11/2022
Full submission received from Applicant 06/01/2023
Preliminary review sent to Applicant 31/05/2023
NCPE assessment re-commenced 29/06/2023
Factual accuracy sent to Applicant 27/10/2023
NCPE assessment re-commenced 06/11/2023
NCPE assessment completed 29/11/2023
NCPE assessment outcome The NCPE recommends that Palforzia® not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.